Literature DB >> 2379155

Epidermal growth factor and transforming growth factor alpha induce ascitic fluid in mice.

E Ohmura1, T Tsushima, Y Kamiya, M Okada, N Onoda, K Shizume, H Demura.   

Abstract

Recent studies have suggested that pleural or peritoneal effusion associated with metastatic tumors is induced by some mediators produced by the tumor cells. We studied the ability of well-characterized peptide growth factors to produce ascites in mice. Peritoneal administration of epidermal growth factor (EGF, 10 to 40 micrograms/mouse/wk) or transforming growth factor alpha (TGF-alpha, 10 to 40 micrograms/mouse/wk) via osmotic minipumps resulted in formation of bloody ascites. The amount of ascites produced was dependent on the dose of growth factors. Vehicle alone or insulin-like growth factor I (40 micrograms/mouse/wk) was without effect. Indomethacin, a blocker of prostaglandin synthesis, significantly reduced the ascites accumulation induced by EGF, suggesting that prostaglandins are involved in ascites formation induced by EGF. Dexamethasone was also effective in attenuating the effect of EGF. Thus, it is possible that peritoneal effusion associated with disseminated tumors is, at least in part, due to EGF-like materials (most likely TGF-alpha) produced by tumor cells. The mechanism by which these peptides induce bloody ascites is not known for certain, but it may be due to the reported activity for neovascularization or increased vascular permeability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379155

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Epidermal growth factor-like activity and epidermal growth factor-receptors in human primary breast cancer.

Authors:  Z Kahán; M Szücs; M Vecsernyés; S Eckhardt
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

2.  Suppression by interferon-gamma of tumor cell-induced increase in mesothelial permeability.

Authors:  A Uchiyama; H Kitsuki; H Shimura; M Torisu
Journal:  Clin Exp Metastasis       Date:  1992-11       Impact factor: 5.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.